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Every 100th patient appearing on the doorstep of a busy first opinion practice will be 2 
presented with seizures and two thirds of these patients will have epilepsy (Heske and 3 
others 2014; Kearsley-Fleet and others 2013). Despite the frequency in occurrence and a 4 
plethora of studies been published in the field, the clinician remains puzzled of what 5 
terminology is the correct one to use, how to diagnose the different types of epilepsy, how 6 
and when to treat best and when change in treatment is necessary?  7 
In 2015, a group of Veterinary Neurology Specialists and Non-specialists came together to 8 
form the International Veterinary Epilepsy Task Force (IVETF). The IVETF’s main aim is “to 9 
provide the veterinary community, breeders and dog (and in part cat) owners with 10 
consensus statements on the key areas in the field of epilepsy”(Volk 2015). The IVETF wants 11 
to represent the “chain of care” involving a broad range of stakeholders (veterinary and 12 
human neurologists and neuroscientists, practitioners, neuropharmacologists and 13 
neuropathologists) to ensure that the produced consensus statements are pragmatic and 14 
‘user-friendly’ for daily use. More than 25 co-authors were involved in the process of 15 
developing seven consensus statements: 16 
1. International Veterinary Epilepsy Task Force consensus report on epilepsy 
definition, classification and terminology in companion animals (Berendt and others 
2015) 
2. International Veterinary Epilepsy Task Force Consensus Proposal: Diagnostic 17 
approach to epilepsy in dogs (De Risio and others 2015) 18 
3. International Veterinary Epilepsy Task Force current understanding of idiopathic 19 
epilepsy of genetic or suspected genetic origin in purebred dogs (Huelsmeyer and 20 
others 2015) 21 
4. International Veterinary Epilepsy Task Force consensus proposal: Medical treatment 22 
of canine epilepsy in Europe (Bhatti and others 2015) 23 
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5. International Veterinary Epilepsy Task Force Consensus Proposal: Outcome of 24 
therapeutic interventions in canine and feline epilepsy (Potschka and others 2015) 25 
6. International Veterinary Epilepsy Task Force recommendations for a veterinary 26 
epilepsy-specific MRI protocol (Rusbridge and others 2015) 27 
7. International Veterinary Epilepsy Task Force recommendations for systematic 28 
sampling and processing of brains from epileptic dogs and cats (Matiasek and others 29 
2015) 30 
In 2016, a complimentary consensus statement about seizure management was published 31 
under the umbrella of the American College of Veterinary Internal Medicine (ACVIM) 32 
(Podell and others 2016). The ACVIM’s and IVETF’s consensus statements are based on 33 
evidence-based medicine, but also consider collective expertise where such evidence is 34 
conflicting or lacking. All the consensus statements are freely available online for the 35 
interested reader1. A potted version of some of the highlights can be found below: 36 
What terminology is the correct one to use (Berendt and others 2015)?  37 
How best to talk the talk in Epilepsy - the IVETF proposed to differentiate between the term 38 
seizure and epileptic seizure. The term seizure can be used for any sudden occurring, brief 39 
and transient episode and does not necessarily imply that the event is epileptic. It is 40 
therefore better to use the term epileptic seizure when you are certain of the nature of the 41 
episode. Epileptic seizures are defined as “manifestations of excessive synchronous, usually 42 
self-limiting epileptic activity of neurons in the brain. This results in a transient occurrence 43 
of signs which may be characterised by short episodes with convulsions or focal motor, 44 
autonomic or behavioural features and due to abnormal excessive and/or synchronous 45 
epileptic neuronal activity in the brain”(Berendt and others 2015).  46 





Epileptic seizures can be differentiated into focal and generalised epileptic seizures, and 47 
focal epileptic seizures can evolve into generalised epileptic seizures.  Focal epileptic 48 
seizures originate within a neural network of one cerebral hemisphere. The onset and the 49 
resulting clinical signs are consistent from one epileptic seizure to another. An example 50 
could be the animal presents with epileptic seizures which always start with a twitching of 51 
its right facial muscles. Focal epileptic seizures are often asymmetrical in presentation. On 52 
the other hand, a generalised epileptic seizure is characterised by major involvement of both 53 
cerebral hemispheres. Epileptic seizures can further be described depending on their 54 
expression(s) of autonomic, motor or behavioural features.  55 
The IVETF defined epilepsy conceptually as a brain disease which is “characterised by an 56 
enduring predisposition to generate epileptic seizures”, however, realised that a more 57 
practical definition was needed. The definition for epilepsy which can be used in daily 58 
practice is that epilepsy is defined as “at least two unprovoked epileptic seizures >24 h 59 
apart”. The IVETF proposed not to use the term epilepsy for epileptic seizures which are 60 
secondary or reactive to a metabolic or toxic transient disturbance in function, which when 61 
rectified will result in a cessation of epileptic activity. The term reactive seizures should be 62 
used for these.  63 
 64 
How to diagnose the different types of epilepsy (Berendt and others 2015; De Risio and 65 
others 2015)? 66 
After the clinician has determined that the animal has recurrent epileptic seizures, the cause 67 
of the epileptic seizures need to be determined. Broadly speaking, the IVETF proposed to 68 
differentiate idiopathic epilepsy from structural epilepsy. The former term cryptogenic 69 
(possible symptomatic) epilepsy has been heavily discussed in human medicine, as some of 70 
them were identified later to be genetic in origin and this resulted human medicine to move 71 
away from this term and use the term epilepsy of unknown cause for epilepsy in which an 72 
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underlying cause could not be identified. This term was also listed in the IVETF statement 73 
as a “bucket term” for all the epilepsies which cannot be classified as idiopathic or structural 74 
epilepsy.  75 
Structural epilepsy is caused by any disease which alters the brain structure such as 76 
vascular, inflammatory/infectious, traumatic, anomalous/developmental, neoplastic and 77 
degenerative diseases. After long debate the IVETF continues to recommend to use the term 78 
idiopathic epilepsy as it is well established. However, idiopathic epilepsy should be seen as 79 
a framework term which can be further differentiated into  80 
1. “Idiopathic epilepsy (genetic epilepsy)—a causative gene for epilepsy has been 81 
identified/confirmed genetic background” (Berendt and others 2015). 82 
2. “Idiopathic epilepsy (suspected genetic epilepsy)” – this applies for those cases 83 
where you have family or breed history of epilepsy (see also Huelsmeyer and others 84 
2015).   85 
3. “Idiopathic epilepsy (epilepsy of unknown cause)—epilepsy in which the nature of 86 
the underlying cause is as yet unknown and with no indication of structural 87 
epilepsy”.   88 
  89 
The IVETF also provided guidelines of how to confirm idiopathic epilepsy diagnostically 90 
and introduced a three tier level of confidence for the diagnosis of idiopathic epilepsy (De 91 
Risio and others 2015). In brief, the first tier can be diagnosed by any first opinion 92 
practitioner if an animal has “≥ 2 unprovoked epileptic seizures occurring ≥ 24h apart, age 93 
at epileptic seizure onset 6 months to 6 years, unremarkable inter-ictal physical and 94 
neurological examination, no clinically significant abnormalities on minimum database 95 
blood tests and urinalysis”. A family history of epilepsy adds strength to the diagnosis. The 96 
next level of confidence can be reached (tier 2) by having also an unremarkable dynamic 97 
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bile acid test, MRI (epilepsy-specific MRI protocol (Rusbridge and others 2015)) and CSF 98 
analysis. The highest level of confidence (tier 3) can be reached when in addition to the 99 
requirements fulfilled in tier 1 and 2 characteristic EEG changes are present. 100 
 101 
How and when to treat best and when change in treatment is necessary (Bhatti and others 102 
2015; Podell and others 2016)? 103 
The ACVIM’s and IVETF’s consensus statements agree in most parts of when medical 104 
treatment should be initiated. Treatment should be started when structural epilepsy is 105 
present, the period between seizures is equal or less than 6 months, the frequency of seizures 106 
is increasing over the last 3 inter-ictal periods, the animal had a status epilepticus, cluster 107 
seizures, severe or debilitating postictal signs. Both also agree that the evidence 108 
(Charalambous and others 2014; Charalambous and others 2016) is strongest for starting an 109 
otherwise healthy dog with epilepsy on Imepitoin or Phenobarbital. The IVETF, however, 110 
pointed out that in Europe, Imepitoin should only be prescribed for dogs with idiopathic 111 
epilepsy which have single generalised epileptic seizures.  112 
The IVETF’s aim is to ideally achieve seizure freedom or at least an “extension of the inter-113 
seizure interval to three times the longest pre-treatment inter-seizure interval and for a 114 
minimum of three months”(Bhatti and others 2015; Potschka and others 2015). The IVETF 115 
does recognizes partial treatment success which is characterized by an at least 50% 116 
reduction in seizure frequency and/or seizure severity. It is known that a risk factor for 117 
poorer seizure control is a high seizure density (Packer and others 2014) and patients with 118 
cluster seizures might need to be treated more aggressively sooner.  If treatment is not 119 
successful and/or treatment is not well tolerated treatment might need to be altered. Other 120 
factors apart from treatment success which might need to be considered when selecting a 121 
second anti-epileptic drug is the selection of a drug with a different mechanism of action, 122 
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potential harmful drug-interactions and a risk-benefit analysis of polypharmacy versus 123 
quality of life (Podell and others 2016).  124 
The IVETF mainly recommends potassium bromide as an add-on medication, considering 125 
also local legal frameworks (Bhatti and others 2015). The ACVIM provides only a moderate 126 
level of recommendation of which drug best to chose from for second line treatment; Drugs 127 
mentioned are Phenobarbital, potassium bromide, Levetiracetam and Zonisamide (Podell 128 
and others 2016). The ACVIM also provides recommendations about non-pharmacological 129 
treatment options and the potential of novel diets for the management of epilepsy (Podell 130 
and others 2016), which might improve seizure control and reduce behavioural 131 
comorbidities(Law and others 2015; Packer and others 2016). Both groups highlight the 132 
importance of owner education and the importance of considering quality of life in the 133 
successful management of epilepsy.  134 
In conclusion, as a busy clinician one can easily not see the forest for the trees in epilepsy. 135 
Epilepsy is a rather complex disease and can be challenging to diagnose and treat. The recent 136 
published consensus statements are useful resources to help give an expert overview of 137 
what is relevant.     138 
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